Cargando…
Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score
PURPOSE: Although the incidence of distant relapse is decreasing, 20–30% of patients with early breast cancer die of metastasis. The aim of this study is to characterize patients with metastasis-free survival(MFS) less than 5 years, to analyze the most probable site of metastases according to the in...
Autores principales: | Ebner, Florian, Salmen, Jessica, Dayan, Davut, Kiesel, Matthias, Wolters, Regine, Janni, Wolfgang, Wöckel, Achim, Wischnewsky, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147811/ https://www.ncbi.nlm.nih.gov/pubmed/36917303 http://dx.doi.org/10.1007/s10549-023-06898-z |
Ejemplares similares
-
BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients
por: Wischnewsky, Manfred, et al.
Publicado: (2021) -
Association of social service counseling in breast cancer patients with financial problems, role functioning and employment—results from the prospective multicenter BRENDA II study
por: Dayan, Davut, et al.
Publicado: (2022) -
Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy—results from the prospective multi-center BRENDA II study
por: Leinert, Elena, et al.
Publicado: (2022) -
Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
por: Ebner, Florian, et al.
Publicado: (2019) -
BRENDA in 2017: new perspectives and new tools in BRENDA
por: Placzek, Sandra, et al.
Publicado: (2017)